Navratil Tomas, the Chief Development Officer at Glaukos Corp, has disclosed two transactions involving common stock in a recent SEC filing. The report, filed on November 3, 2026, highlights the acquisition of shares to meet tax obligations associated with vested restricted stock units. This disclosure is significant as it illustrates the ongoing compensation practices within the surgical and medical instruments sector.

Background

Glaukos Corp, identified by the Central Index Key (CIK) 0001192448, operates in the surgical and medical instruments industry, specifically under the SIC code 3841. The company is incorporated in Delaware and has its business address in Aliso Viejo, California. Recent filings include various forms, with the most recent being Form 4, filed on November 3, 2026, and prior forms indicating continued activity in stock transactions.

What the Filing Says

The SEC filing details two transactions dated April 9, 2024. The first transaction involved 495 shares of common stock acquired at a price of $87.61 per share. The second transaction involved 260 shares at a price of $93.23 per share. Both transactions were executed to cover tax withholding obligations upon the vesting of restricted stock units. Notably, the filing states, "This transaction is exempt pursuant to Rule 16b-3." Following these transactions, Tomas holds a total of 68,536 shares, including 37,328 restricted stock units that have not yet vested.

Impact

This update may affect various stakeholders, including Glaukos Corp's management team and investors. The transactions reflect the company's approach to managing executive compensation and tax obligations, which can influence investor perceptions and corporate governance practices.

What's Next

The filing does not say what happens next.